STAAR Surgical Company - 10-Q Summary
Business Context and Reporting Period
Company: STAAR Surgical Company
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: April 4, 2003
Business Overview: The Company develops, manufactures, and distributes medical devices for minimally invasive ophthalmic surgery, primarily in the cataract, refractive, and glaucoma segments. Operations are global, with significant revenue from international markets (53% of total revenue).
Key Financial Metrics
| Metric (in thousands) | Q1 2003 | Q1 2002 |
|---|---|---|
| Total Revenues | $12,826 | $11,731 |
| Gross Profit | $6,979 | $5,712 |
| Gross Margin | 54.4% | 48.7% |
| Operating Loss | $(645) | $(1,768) |
| Net Loss | $(747) | $(997) |
| Loss Per Share (Basic/Diluted) | $(0.04) | $(0.06) |
| Cash and Equivalents | $399 | $764 |
| Notes Payable (Outstanding) | $2,100 (approx) | $2,800 (approx) |
| Net Working Capital | $6,817 | $7,000 (approx) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 9.3% year-over-year to $12.8 million. This was driven by a 31% increase in distributed products in Germany and a 37% increase in international sales of the Implantable Contact Lens (ICL).
- Margin Expansion: Gross profit margin improved to 54.4% from 48.7%. This improvement is attributed to replacing high-cost inventory with lower-cost inventory and increased sales of higher-margin ICL products.
- Loss Reduction: Net loss decreased by 25% to $747,000, compared to $997,000 in the prior year. Operating loss narrowed significantly from $1.768 million to $645,000.
- Product Mix: U.S. sales declined 7% due to a 20% drop in unit volume of single-piece silicone IOLs caused by delivery system issues. This was offset by international growth.
- Other Income: Other income turned positive ($245,000) compared to an expense of $120,000 in the prior year, driven by earnings from a Japanese joint venture and interest income on notes from former officers.
Guidance, Outlook, and Risks
Management Commentary:
- Outlook: Management expects IOL sales in the U.S. to increase in the second half of the year as delivery system issues are resolved. Days Sales Outstanding (DSO) are expected to remain between 45 and 50 days.
- Liquidity: Cash decreased by $610,000 during the quarter primarily due to paying down domestic notes payable. The Company maintains a $3.0 million domestic line of credit (extended to March 2004) and international facilities in Switzerland and Germany.
- Covenants: The Company is currently in compliance with financial covenants. Operating cash flow and income covenants commence in the third quarter of 2003.
Risks and Contingencies:
- History of Losses: The Company has an accumulated deficit of $42.2 million and has reported losses for the last three fiscal years.
- Financing Dependence: The Company relies on external funding. Failure to meet loan covenants could lead to foreclosure on assets, as substantially all assets are pledged as collateral.
- Regulatory and Product Risks: Risks include product recalls, failure to obtain regulatory approvals for new products, and intense competition from larger firms (e.g., Alcon, Bausch & Lomb).
- Foreign Exchange: Significant exposure to currency fluctuations (Euro, Swiss Franc, Australian Dollar) impacts reported revenues and margins.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new operating cash flow and income covenants commencing in Q3 2003.
- Inventory Valuation: Confirm the sustainability of the gross margin improvement driven by inventory replacement and monitor for potential write-downs.
- U.S. Sales Recovery: Monitor the resolution of the single-piece silicone IOL delivery system issues and subsequent U.S. sales trends.
- Liquidity Position: Assess the adequacy of cash reserves ($399k) relative to working capital needs and upcoming debt obligations.
- Legal Proceedings: Review the status of the shareholder derivative suit (dismissed without prejudice in April 2003) and any potential future litigation costs.